publication date: May. 4, 2018
CPRIT announces New Seed Award for early-stage oncology startups
The Cancer Prevention and Research Institute of Texas is unveiling a new award mechanism targeting early-stage oncology startup companies. Under this program, known as the Seed Award, companies can apply for up to $3 million in nondilutive funding to support development of innovative cancer therapeutics, diagnostics or tools.
The Seed Award is designed for projects that are too early in their development to be competitive for CPRIT’s two other Product Development awards: the Texas Company Award and the Company Relocation Award. The goal of the Seed Award is to assist startups in bridging the gap between translational research and product development, thus bringing disruptive cancer-fighting technologies to market.
To qualify for up to $3 million in project funding, companies must currently be based in Texas or commit to relocate to Texas upon receipt of award. Companies interested in this award will need to apply and undergo CPRIT’s peer review process.
Seed Award Requests for Application for FY 2019 Cycle 1 will be released in June 2018, with applications due in August 2018. The award will be announced in February 2019.
Cycle 2s RFAs will be released December 2018, with applications due in February 2019 and award notification in August 2019. Similar schedules are planned for FY 2020 and FY 2021.
Please visit the CPRIT website, and select Grant Information to receive updates on CPRIT funding opportunities.